An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy
Summary Background Up to 50% of adolescents who undergo metabolic and bariatric surgery (MBS) have obesity 3 years post‐MBS, placing them at continued risk for the consequences of obesity. Objectives We conducted an open‐label, 16‐week pilot study of liraglutide in adolescents with obesity after sle...
Gespeichert in:
| Veröffentlicht in: | Pediatric obesity 2024-11, Vol.19 (11), p.e13154-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 11 |
| container_start_page | e13154 |
| container_title | Pediatric obesity |
| container_volume | 19 |
| creator | Zenno, Anna Nwosu, Ejike E. Fatima, Syeda Z. Nadler, Evan P. Mirza, Nazrat M. Brady, Sheila M. Turner, Sara A. Yang, Shanna B. Lazareva, Julia Te‐Vasquez, Jennifer A. Chen, Kong Y. Chung, Stephanie T. Yanovski, Jack A. |
| description | Summary
Background
Up to 50% of adolescents who undergo metabolic and bariatric surgery (MBS) have obesity 3 years post‐MBS, placing them at continued risk for the consequences of obesity.
Objectives
We conducted an open‐label, 16‐week pilot study of liraglutide in adolescents with obesity after sleeve gastrectomy (SG) to investigate liraglutide effects on weight and body mass index (BMI) post‐SG.
Methods
Adolescents aged 12–20.99 years with obesity and a history of SG ≥1 year prior were enrolled. Liraglutide was initiated at 0.6 mg/day, escalated weekly to a maximum of 3 mg/day, with treatment duration 16 weeks. Fasting laboratory assessments and an oral glucose tolerance test were performed at baseline and end‐treatment.
Results
A total of 43 participants were screened, 34 initiated liraglutide (baseline BMI 41.2 ± 7.7 kg/m2), and 31 (91%) attended the end‐treatment visit. BMI decreased by 4.3% (p |
| doi_str_mv | 10.1111/ijpo.13154 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3089504590</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089504590</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2464-6342b9d37726e4f34564594170c66dade0fc5806bcd02fee0fea726beec868583</originalsourceid><addsrcrecordid>eNp9kMFO3DAQhq2qqKyASx8AWeKCkHYZx46THFcI2q2Q4EDPlhNPwIs3DrHDKjceoc_YJ6npUg4cOhfPSJ8__foJ-cpgwdKc23XvF4yzXHwiswxEMZecwef3HbJ9chTCGtJIYBLEF7LPKwY8E8WMmGVHfY_d75dfTtfoKJNp3SI-0hBHM1HfUmcHfe_GaA1S21FtvMPQYBcD3dr4QH2NwcaJ9j7E9Dk4xGek9zrEAZvoN9Mh2Wu1C3j09h6Qn1eXdxff59c331YXy-t5kwkpUliR1ZXhRZFJFC0XuRR5JVgBjZRGG4S2yUuQdWMgazGdqBNaIzalLPOSH5DTnbcf_NOIIaqNTUGd0x36MSgOZZVDckJCTz6gaz8OXUqnOGMFB86rKlFnO6oZfAgDtqof7EYPk2KgXutXr_Wrv_Un-PhNOdYbNO_ov7ITwHbA1jqc_qNSqx-3NzvpH_6Mkj0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3117303399</pqid></control><display><type>article</type><title>An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zenno, Anna ; Nwosu, Ejike E. ; Fatima, Syeda Z. ; Nadler, Evan P. ; Mirza, Nazrat M. ; Brady, Sheila M. ; Turner, Sara A. ; Yang, Shanna B. ; Lazareva, Julia ; Te‐Vasquez, Jennifer A. ; Chen, Kong Y. ; Chung, Stephanie T. ; Yanovski, Jack A.</creator><creatorcontrib>Zenno, Anna ; Nwosu, Ejike E. ; Fatima, Syeda Z. ; Nadler, Evan P. ; Mirza, Nazrat M. ; Brady, Sheila M. ; Turner, Sara A. ; Yang, Shanna B. ; Lazareva, Julia ; Te‐Vasquez, Jennifer A. ; Chen, Kong Y. ; Chung, Stephanie T. ; Yanovski, Jack A.</creatorcontrib><description>Summary
Background
Up to 50% of adolescents who undergo metabolic and bariatric surgery (MBS) have obesity 3 years post‐MBS, placing them at continued risk for the consequences of obesity.
Objectives
We conducted an open‐label, 16‐week pilot study of liraglutide in adolescents with obesity after sleeve gastrectomy (SG) to investigate liraglutide effects on weight and body mass index (BMI) post‐SG.
Methods
Adolescents aged 12–20.99 years with obesity and a history of SG ≥1 year prior were enrolled. Liraglutide was initiated at 0.6 mg/day, escalated weekly to a maximum of 3 mg/day, with treatment duration 16 weeks. Fasting laboratory assessments and an oral glucose tolerance test were performed at baseline and end‐treatment.
Results
A total of 43 participants were screened, 34 initiated liraglutide (baseline BMI 41.2 ± 7.7 kg/m2), and 31 (91%) attended the end‐treatment visit. BMI decreased by 4.3% (p < 0.001) with liraglutide. Adolescents who had poor initial response to SG (<20% BMI reduction at BMI nadir) had less weight loss with liraglutide. Fasting glucose and haemoglobin A1C concentrations significantly decreased. There were no serious treatment‐emergent adverse events reported.
Conclusions
Liraglutide treatment was feasible and associated with a BMI reduction of 4.3% in adolescents who had previously undergone SG, quantitatively similar to results obtained in adolescents with obesity who have not undergone MBS.</description><identifier>ISSN: 2047-6302</identifier><identifier>ISSN: 2047-6310</identifier><identifier>EISSN: 2047-6310</identifier><identifier>DOI: 10.1111/ijpo.13154</identifier><identifier>PMID: 39103247</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Inc</publisher><subject>adolescence ; Antidiabetics ; bariatric surgery ; Body mass index ; Gastrointestinal surgery ; GLP1 ; Obesity ; pharmacotherapy ; Teenagers ; Weight control ; weight loss</subject><ispartof>Pediatric obesity, 2024-11, Vol.19 (11), p.e13154-n/a</ispartof><rights>Published 2024. This article is a U.S. Government work and is in the public domain in the USA.</rights><rights>2024 World Obesity Federation</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2464-6342b9d37726e4f34564594170c66dade0fc5806bcd02fee0fea726beec868583</cites><orcidid>0000-0001-6989-0417 ; 0000-0001-8542-1637</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijpo.13154$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijpo.13154$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39103247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zenno, Anna</creatorcontrib><creatorcontrib>Nwosu, Ejike E.</creatorcontrib><creatorcontrib>Fatima, Syeda Z.</creatorcontrib><creatorcontrib>Nadler, Evan P.</creatorcontrib><creatorcontrib>Mirza, Nazrat M.</creatorcontrib><creatorcontrib>Brady, Sheila M.</creatorcontrib><creatorcontrib>Turner, Sara A.</creatorcontrib><creatorcontrib>Yang, Shanna B.</creatorcontrib><creatorcontrib>Lazareva, Julia</creatorcontrib><creatorcontrib>Te‐Vasquez, Jennifer A.</creatorcontrib><creatorcontrib>Chen, Kong Y.</creatorcontrib><creatorcontrib>Chung, Stephanie T.</creatorcontrib><creatorcontrib>Yanovski, Jack A.</creatorcontrib><title>An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy</title><title>Pediatric obesity</title><addtitle>Pediatr Obes</addtitle><description>Summary
Background
Up to 50% of adolescents who undergo metabolic and bariatric surgery (MBS) have obesity 3 years post‐MBS, placing them at continued risk for the consequences of obesity.
Objectives
We conducted an open‐label, 16‐week pilot study of liraglutide in adolescents with obesity after sleeve gastrectomy (SG) to investigate liraglutide effects on weight and body mass index (BMI) post‐SG.
Methods
Adolescents aged 12–20.99 years with obesity and a history of SG ≥1 year prior were enrolled. Liraglutide was initiated at 0.6 mg/day, escalated weekly to a maximum of 3 mg/day, with treatment duration 16 weeks. Fasting laboratory assessments and an oral glucose tolerance test were performed at baseline and end‐treatment.
Results
A total of 43 participants were screened, 34 initiated liraglutide (baseline BMI 41.2 ± 7.7 kg/m2), and 31 (91%) attended the end‐treatment visit. BMI decreased by 4.3% (p < 0.001) with liraglutide. Adolescents who had poor initial response to SG (<20% BMI reduction at BMI nadir) had less weight loss with liraglutide. Fasting glucose and haemoglobin A1C concentrations significantly decreased. There were no serious treatment‐emergent adverse events reported.
Conclusions
Liraglutide treatment was feasible and associated with a BMI reduction of 4.3% in adolescents who had previously undergone SG, quantitatively similar to results obtained in adolescents with obesity who have not undergone MBS.</description><subject>adolescence</subject><subject>Antidiabetics</subject><subject>bariatric surgery</subject><subject>Body mass index</subject><subject>Gastrointestinal surgery</subject><subject>GLP1</subject><subject>Obesity</subject><subject>pharmacotherapy</subject><subject>Teenagers</subject><subject>Weight control</subject><subject>weight loss</subject><issn>2047-6302</issn><issn>2047-6310</issn><issn>2047-6310</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMFO3DAQhq2qqKyASx8AWeKCkHYZx46THFcI2q2Q4EDPlhNPwIs3DrHDKjceoc_YJ6npUg4cOhfPSJ8__foJ-cpgwdKc23XvF4yzXHwiswxEMZecwef3HbJ9chTCGtJIYBLEF7LPKwY8E8WMmGVHfY_d75dfTtfoKJNp3SI-0hBHM1HfUmcHfe_GaA1S21FtvMPQYBcD3dr4QH2NwcaJ9j7E9Dk4xGek9zrEAZvoN9Mh2Wu1C3j09h6Qn1eXdxff59c331YXy-t5kwkpUliR1ZXhRZFJFC0XuRR5JVgBjZRGG4S2yUuQdWMgazGdqBNaIzalLPOSH5DTnbcf_NOIIaqNTUGd0x36MSgOZZVDckJCTz6gaz8OXUqnOGMFB86rKlFnO6oZfAgDtqof7EYPk2KgXutXr_Wrv_Un-PhNOdYbNO_ov7ITwHbA1jqc_qNSqx-3NzvpH_6Mkj0</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Zenno, Anna</creator><creator>Nwosu, Ejike E.</creator><creator>Fatima, Syeda Z.</creator><creator>Nadler, Evan P.</creator><creator>Mirza, Nazrat M.</creator><creator>Brady, Sheila M.</creator><creator>Turner, Sara A.</creator><creator>Yang, Shanna B.</creator><creator>Lazareva, Julia</creator><creator>Te‐Vasquez, Jennifer A.</creator><creator>Chen, Kong Y.</creator><creator>Chung, Stephanie T.</creator><creator>Yanovski, Jack A.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6989-0417</orcidid><orcidid>https://orcid.org/0000-0001-8542-1637</orcidid></search><sort><creationdate>202411</creationdate><title>An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy</title><author>Zenno, Anna ; Nwosu, Ejike E. ; Fatima, Syeda Z. ; Nadler, Evan P. ; Mirza, Nazrat M. ; Brady, Sheila M. ; Turner, Sara A. ; Yang, Shanna B. ; Lazareva, Julia ; Te‐Vasquez, Jennifer A. ; Chen, Kong Y. ; Chung, Stephanie T. ; Yanovski, Jack A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2464-6342b9d37726e4f34564594170c66dade0fc5806bcd02fee0fea726beec868583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>adolescence</topic><topic>Antidiabetics</topic><topic>bariatric surgery</topic><topic>Body mass index</topic><topic>Gastrointestinal surgery</topic><topic>GLP1</topic><topic>Obesity</topic><topic>pharmacotherapy</topic><topic>Teenagers</topic><topic>Weight control</topic><topic>weight loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zenno, Anna</creatorcontrib><creatorcontrib>Nwosu, Ejike E.</creatorcontrib><creatorcontrib>Fatima, Syeda Z.</creatorcontrib><creatorcontrib>Nadler, Evan P.</creatorcontrib><creatorcontrib>Mirza, Nazrat M.</creatorcontrib><creatorcontrib>Brady, Sheila M.</creatorcontrib><creatorcontrib>Turner, Sara A.</creatorcontrib><creatorcontrib>Yang, Shanna B.</creatorcontrib><creatorcontrib>Lazareva, Julia</creatorcontrib><creatorcontrib>Te‐Vasquez, Jennifer A.</creatorcontrib><creatorcontrib>Chen, Kong Y.</creatorcontrib><creatorcontrib>Chung, Stephanie T.</creatorcontrib><creatorcontrib>Yanovski, Jack A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric obesity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zenno, Anna</au><au>Nwosu, Ejike E.</au><au>Fatima, Syeda Z.</au><au>Nadler, Evan P.</au><au>Mirza, Nazrat M.</au><au>Brady, Sheila M.</au><au>Turner, Sara A.</au><au>Yang, Shanna B.</au><au>Lazareva, Julia</au><au>Te‐Vasquez, Jennifer A.</au><au>Chen, Kong Y.</au><au>Chung, Stephanie T.</au><au>Yanovski, Jack A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy</atitle><jtitle>Pediatric obesity</jtitle><addtitle>Pediatr Obes</addtitle><date>2024-11</date><risdate>2024</risdate><volume>19</volume><issue>11</issue><spage>e13154</spage><epage>n/a</epage><pages>e13154-n/a</pages><issn>2047-6302</issn><issn>2047-6310</issn><eissn>2047-6310</eissn><abstract>Summary
Background
Up to 50% of adolescents who undergo metabolic and bariatric surgery (MBS) have obesity 3 years post‐MBS, placing them at continued risk for the consequences of obesity.
Objectives
We conducted an open‐label, 16‐week pilot study of liraglutide in adolescents with obesity after sleeve gastrectomy (SG) to investigate liraglutide effects on weight and body mass index (BMI) post‐SG.
Methods
Adolescents aged 12–20.99 years with obesity and a history of SG ≥1 year prior were enrolled. Liraglutide was initiated at 0.6 mg/day, escalated weekly to a maximum of 3 mg/day, with treatment duration 16 weeks. Fasting laboratory assessments and an oral glucose tolerance test were performed at baseline and end‐treatment.
Results
A total of 43 participants were screened, 34 initiated liraglutide (baseline BMI 41.2 ± 7.7 kg/m2), and 31 (91%) attended the end‐treatment visit. BMI decreased by 4.3% (p < 0.001) with liraglutide. Adolescents who had poor initial response to SG (<20% BMI reduction at BMI nadir) had less weight loss with liraglutide. Fasting glucose and haemoglobin A1C concentrations significantly decreased. There were no serious treatment‐emergent adverse events reported.
Conclusions
Liraglutide treatment was feasible and associated with a BMI reduction of 4.3% in adolescents who had previously undergone SG, quantitatively similar to results obtained in adolescents with obesity who have not undergone MBS.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Inc</pub><pmid>39103247</pmid><doi>10.1111/ijpo.13154</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6989-0417</orcidid><orcidid>https://orcid.org/0000-0001-8542-1637</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-6302 |
| ispartof | Pediatric obesity, 2024-11, Vol.19 (11), p.e13154-n/a |
| issn | 2047-6302 2047-6310 2047-6310 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3089504590 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | adolescence Antidiabetics bariatric surgery Body mass index Gastrointestinal surgery GLP1 Obesity pharmacotherapy Teenagers Weight control weight loss |
| title | An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T17%3A02%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20open%E2%80%90label%2016%E2%80%90week%20study%20of%20liraglutide%20in%20adolescents%20with%20obesity%20post%E2%80%90sleeve%20gastrectomy&rft.jtitle=Pediatric%20obesity&rft.au=Zenno,%20Anna&rft.date=2024-11&rft.volume=19&rft.issue=11&rft.spage=e13154&rft.epage=n/a&rft.pages=e13154-n/a&rft.issn=2047-6302&rft.eissn=2047-6310&rft_id=info:doi/10.1111/ijpo.13154&rft_dat=%3Cproquest_cross%3E3089504590%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3117303399&rft_id=info:pmid/39103247&rfr_iscdi=true |